Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QT(c) interval)

Clinical Therapeutics

Volumn 21, Issue 5, 1999, Pages 818-828

  Morganroth, Joel ^a,e   Talbot, George H ^b   Dorr, Mary B ^b   Johnson, Robert D ^b,c   Geary, William ^b   Magner, David ^b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANOFI   (France)

^c ELI LILLY AND COMPANY   (United States)

^d Astra Pharmaceuticals   (United States)

^e Premier Research   (United States)

Author keywords

Electrocardiography; Maximum plasma concentration; QT(c) interval; Sparfloxacin

Indexed keywords

PLACEBO; SPARFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HEART REPOLARIZATION; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

EID: 0032968204     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80004-6     Document Type: Article

References (10)

1. 1. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55.
2. 2. Nakashima M, Vernatsu M, Takiguchi Y. Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin. Rinsho-Yakuri. 1991;7:1639-1684.
3. 3. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother. 1996;37(Suppl A):161-167.
4. 4. Goa KL, Bryson HM, Markham A. Sparfloxacin: A review of its antimicrobial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs. 1997; 53:700-725.
5. 5. Ortqvist A, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest. 1996;110: 1499-1506.
6. 6. Montay G. Pharmacokinetics of sparfloxacin in human volunteers and patients: A review. J Antimicrob Chemother. 1996; 37(Suppl A):27-39.
7. 7. Montay G, Bruno R, Vergniol JC, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol. 1994;34:1071-1076.
8. 8. Raxar® package insert. Research Triangle Park, NC: Glaxo Wellcome, Inc.; 1999.
9. 9. Erythromycin, Physicians' Desk Reference®. Montvale, NJ: Medical Economics Co., Inc.; 1998:438-445.
10. 10. Sparfloxacin package insert. Collegeville, Pa: Rhône-Poulenc Rorer Pharmaceuticals, Inc.; 1997.